Millennium acquires rights to proteasome inhibitors and related synthesis techonology - agreement to augment company's proteasome inhibitor program-.(Millennium Pharmaceuticals Inc.)

BIOTECH Patent News, May, 2004

Millennium Pharmaceuticals, Inc. (Cambridge, MA) today announced it has signed a research agreement with Harvard University and Professor E.J. Corey for a family of proteasome inhibitors and a related chemical synthesis process. Millennium intends to utilize the agreement to enhance the Company's ongoing efforts to develop next-generation proteasome inhibitors, building upon the success of its first-in-class proteasome inhibitor, VELCADE(R) (bortezomib) for Injection.

"As the world leader in the field of proteasome inhibition, this collaboration represents an exciting opportunity for us to enhance our unparalleled knowledge base and further explore the biology and chemistry surrounding the proteasome," said Robert Tepper, M.D., president, research and...

Read the rest of this article with a Free Trial at HighBeam Research.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works.